Wolfe Research on Insmed (INSM): 'expect stock to converge toward PT over next few quarters'

March 23, 2026 9:47 AM

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $178.00 price target on Insmed (NASDAQ: INSM)The analyst commented, "Stock ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found